Von Willebrand DiseasesPhase 3EMPOWERNCT06205095
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
A Phase 3 study testing Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII in people with Von Willebrand Diseases, run by Unity Health Toronto at 2 sites in Canada.
Trial summary
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Von Willebrand Diseases
- What is being tested?
- Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 2 sitesCanada
- Study dates
- 21 Oct 2024to Sep 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient capable of providing informed consent;
- Female patients with HMB over the age of 18 years, for whom prophylactic treatment with Wilate® is deemed clinically appropriate according to the medical discretion (based on their expert opinion given consideration of the patient's bleeding history and responsiveness to treatment) of the treating hemostasis-focused physician practicing at a Hemophilia Treatment Center;
- Modified PBAC score > 100 at screening;
- Patients with a diagnosis of inherited von Willebrand disease (any type);
- Stable treatment for HMB and iron deficiency anemia for 3 cycles before entering the study and anticipated to remain unchanged for the duration of the study;
- Patients willing to have an infusion administered by a nurse over the course of the study period;
- Patients who agree to use only the feminine hygiene products supplied by the sponsor.
Who cannot join
- Diagnosed with any other known bleeding disorder;
- Pregnancy or plans to become pregnant within the duration of the study;
- Breastfeeding or plans to breastfeed within the duration of the study;
- Known hypersensitivity reactions to human plasma-derived products or any ingredient in the formulation;
- Known antibodies to VWF or FVIII;
- Severe liver disease;
Show all 11Show fewer
- Anticipated initiation of the following: oral, transdermal, injectable, and vaginal ring hormonal contraceptives; GnRH analogues; or a hormonal intrauterine device (IUD) within the study period;
- Anticipated elective procedure that is expected to require intensive treatment with VWF or FVIII for >10 days during the study period;
- Patients with >2 risk factors for VTE (risk factors are determined at discretion of treating physician) or recent history of thrombosis (i.e. within the last year).
- Patient concurrently receiving desmopressin (desmopressin cannot be taken concurrently with Wilate®, except for in the context of escalation treatment for excessive bleeding).
- Anticipated initiation of any new therapies for the treatment of heavy menstrual bleeding 3 weeks prior to enrollment
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada2 sites, 2 recruiting
- Recruiting
Kingston Health Sciences Centre
Kingston, Ontario
Julie Grabell, +1 613 533 6000 ext. 75223, empower@unityhealth.to
- Recruiting
St. Michael's Hospital
Toronto, Ontario, M5B1W8
Michelle Sholzberg, 4168646060, empower@unityhealth.to
About this study
Official title: A Multi-cEnter, Pilot, Crossover Trial of Prophylactic Wilate coMpared to PlacebO for Heavy Menstrual Bleeding in Patients With Von WillEbRand Disease
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial
Read the detailed description
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial.
For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered.
The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo.
- Conditions
- Von Willebrand Diseases
- Being tested
- Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII, Placebo
- Medical subject headings
- von Willebrand Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIIIDrug
Also called Wilate
Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
PlaceboOther
Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
| Study group | Role | What they receive |
|---|---|---|
| pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care | Experimental | Wilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided. Receives: Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII |
| Placebo and Standard Care | Placebo comparator | Patients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Measured: 2 years
Proportion of participant drop-out at the end of treatment period 1 and 2
Proportion of participant drop-out at the end of treatment period 1 and 2
Measured: 2 years
Proportion of participants with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Proportion of patients with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Measured: 2 years
Number of participants enrolled in 2 years (i.e. ability to enroll at least 10 participants in 2 years)
Ability to enroll at least 10 participants in 2 years
Measured: 2 years
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
Measured: 2 years
Secondary outcomes (22)
Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period
Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period
Measured: At the end of 8 menstrual cycles (approximately 10 days)
The proportion of patients who use of rescue therapy at the end of each treatment period
The proportion of patients who use of rescue therapy (i.e. more than two days of oral tranexamic acid use, additional treatment with Wilate®, additional hormonal therapy for HMB, urgent/emergent gynecological surgery for HMB, treatment with intravenous iron, red blood cell transfusion, or hospital admission for HMB) at the end of each treatment period
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles
Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles
Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of oral tranexamic acid use
Number of days of oral tranexamic acid use
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of Wilate® treatment received
Number of days of Wilate® treatment received
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Duration of menstruation (measured in days)
Duration of menstruation (measured in days)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition
Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Clinically relevant non-major bleed
Clinically relevant non-major bleed
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Hemoglobin levels (g/L)
Hemoglobin levels (g/L)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Ferritin levels (mcg/L)
Ferritin levels (mcg/L)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Use of additional hormonal therapy for heavy menstrual bleeding
Use of additional hormonal therapy for heavy menstrual bleeding
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding
Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Fatigue scores (as measured by the FACIT fatigue scale)
Fatigue scores (as measured by the FACIT fatigue scale)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Short Form-12 Scores
Short Form-12 Scores
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Scores on the individual components of the Short Form-12
Scores on the individual components of the Short Form-12
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)
Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)
Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Number of hypersensitivity infusion reactions
Number of hypersensitivity infusion reactions
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Proportion of participants who development of VWF inhibitors
Proportion of participants who development of VWF inhibitors
Measured: At the end of 8 menstrual cycles (approximately 10 days)
Number of adverse events
Number of adverse events
Measured: 8 cycles
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2024
- Study start21 Oct 2024
- Primary completionDec 2027 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Von Willebrand DiseasesStudies of the same condition, open and under way.
- More trials run by Unity Health TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Unity Health Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06205095
- Sponsor's protocol ID
- 2.5
- Acronym
- EMPOWER
- Status last verified
- Oct 2026
- First submitted
- 18 Dec 2023
- Last updated
- 14 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-cEnter, Pilot, Crossover Trial of Prophylactic Wilate coMpared to PlacebO for Heavy Menstrual Bleeding in Patients With Von WillEbRand Disease
- ClinicalTrials.gov ID
- NCT06205095
- Acronym / sponsor ID
- EMPOWER / 2.5
- Conditions
- Von Willebrand Diseases
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Unity Health TorontoUniversity, hospital or other
- Study start
- 21 Oct 2024 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 12 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial
Detailed description
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial.
For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered.
The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care | Experimental | Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIIIWilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided. |
| Placebo and Standard Care | Placebo comparator | Other: PlaceboPatients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient capable of providing informed consent;
- Female patients with HMB over the age of 18 years, for whom prophylactic treatment with Wilate® is deemed clinically appropriate according to the medical discretion (based on their expert opinion given consideration of the patient's bleeding history and responsiveness to treatment) of the treating hemostasis-focused physician practicing at a Hemophilia Treatment Center;
- Modified PBAC score > 100 at screening;
- Patients with a diagnosis of inherited von Willebrand disease (any type);
- Stable treatment for HMB and iron deficiency anemia for 3 cycles before entering the study and anticipated to remain unchanged for the duration of the study;
Key exclusion criteria (11 listed)
- Diagnosed with any other known bleeding disorder;
- Pregnancy or plans to become pregnant within the duration of the study;
- Breastfeeding or plans to breastfeed within the duration of the study;
- Known hypersensitivity reactions to human plasma-derived products or any ingredient in the formulation;
- Known antibodies to VWF or FVIII;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIIIAlso: WilateWilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1. | Drug | pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care |
| PlaceboPatients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®. | Other | Placebo and Standard Care |
Primary outcome
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Time frame: 2 years
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Proportion of participant drop-out at the end of treatment period 1 and 2
Time frame: 2 years
Proportion of participant drop-out at the end of treatment period 1 and 2
Proportion of participants with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Time frame: 2 years
Proportion of patients with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Number of participants enrolled in 2 years (i.e. ability to enroll at least 10 participants in 2 years)
Time frame: 2 years
Ability to enroll at least 10 participants in 2 years
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
Time frame: 2 years
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
22 secondary outcomes
Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
The proportion of patients who use of rescue therapy at the end of each treatment period
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of oral tranexamic acid use
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of Wilate® treatment received
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Duration of menstruation (measured in days)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Clinically relevant non-major bleed
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Hemoglobin levels (g/L)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Ferritin levels (mcg/L)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Use of additional hormonal therapy for heavy menstrual bleeding
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Fatigue scores (as measured by the FACIT fatigue scale)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Short Form-12 Scores
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Scores on the individual components of the Short Form-12
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of hypersensitivity infusion reactions
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Proportion of participants who development of VWF inhibitors
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of adverse events
Time frame: 8 cycles
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Von Willebrand Diseases
Active, not recruitingObservational study
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Von Willebrand Disease, Type 3
RecruitingObservational study
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Heavy Menstrual Bleeding, Bleeding Disorder
RecruitingPhase 2
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
RecruitingObservational study
Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial Fibrillation
Device-detected Atrial Fibrillation, Subclinical Atrial Fibrillation
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII in people with Von Willebrand Diseases, run by Unity Health Toronto at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact St. Michael's Hospital (4168646060, empower@unityhealth.to), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2 (time frame: 2 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.